Compare IMOS & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IMOS | PHAT |
|---|---|---|
| Founded | 1997 | 2018 |
| Country | Taiwan | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 980.5M | 942.6M |
| IPO Year | N/A | 2019 |
| Metric | IMOS | PHAT |
|---|---|---|
| Price | $27.94 | $14.67 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $17.60 |
| AVG Volume (30 Days) | 24.1K | ★ 812.6K |
| Earning Date | 11-11-2025 | 10-30-2025 |
| Dividend Yield | ★ 2.29% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $748,307,671.00 | $147,190,000.00 |
| Revenue This Year | $5.78 | $218.59 |
| Revenue Next Year | $10.84 | $84.38 |
| P/E Ratio | $129.31 | ★ N/A |
| Revenue Growth | N/A | ★ 460.30 |
| 52 Week Low | $12.78 | $2.21 |
| 52 Week High | $30.98 | $16.27 |
| Indicator | IMOS | PHAT |
|---|---|---|
| Relative Strength Index (RSI) | 59.98 | 53.42 |
| Support Level | $27.55 | $14.61 |
| Resistance Level | $28.36 | $16.27 |
| Average True Range (ATR) | 0.89 | 0.77 |
| MACD | -0.26 | -0.10 |
| Stochastic Oscillator | 53.45 | 21.91 |
ChipMOS TECHNOLOGIES Inc is engaged in the research, development, manufacturing, and sale of high-integration and high-precision integrated circuits and related assembly and testing services. The company's segments include Testing, Assembly, Testing, and Assembly for LCD, OLED, and other Display Panel Driver Semiconductors (LCDD), Bumping, and others. It derives a majority of its revenue from Taiwan followed by Japan, the People's Republic of China, Singapore, and others.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.